Adenoid cystic carcinoma is a rare type of salivary gland cancer. In this study, researchers are assessing the safety and effectiveness of the drug regorafenib in patients with adenoid cystic carcinoma that has come back after treatment or has spread to other parts of the body.
One way regorafenib might inhibit tumor growth is by interfering with the growth of the blood vessels that tumors need to receive nutrients and to spread. The drug is already approved for treating metastatic colorectal cancer and gastrointestinal stromal tumor, but its use in this study is considered investigational. Regorafenib is taken orally (by mouth).